1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
Book a demo
-
  1. My Preqin
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch
  1. My Preqin
Book a demo

DotBio Pte. Ltd.

Have updates for this profile?  Please contribute data

About Financials
= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2017

Location

Singapore Singapore

Primary Industry

Biotechnology

About

Established in 2017 and based in Singapore, DotBio Pte. Ltd. operates as a biotechnology company that develops humanized domain antibody-based immuno-oncology medicines.
Current Investors
HeungKong Group Ltd., ASLAN Pharmaceuticals Pte. Ltd., FuTechVC

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.dotbio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin
31 Mar 2019
0
-
(2,594,845)
-
(2,591,041)
-
(2,594,845)
-
31 Mar 2020
0
-
(1,375,536)
-
(1,360,863)
-
(1,376,377)
-
31 Mar 2021
31 Mar 2022
31 Mar 2023

Unlock the recent years of financials and more for DotBio Pte. Ltd..

Request a demo to see more.

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.
Sign in Request demo